Skip to Main Content
Table 4.

Proportions of Ngn2-positive cells out of the total cycling cells and the cells in particular cell cycle phases

Ngn2 and Ki67  
   Total Ki67-positive cells 1623 
   Ngn2-positive/Ki67-positive 28% 
      Ngn2-positive/Ki67+++ 7% 
      Ngn2-positive/Ki67++ 21% 
      Ngn2-positive/Ki67+ 32% 
   Total Ngn2-positive cells 575 
   Ki67-positive/Ngn2-positive 78% 
Ngn2 and BrdU  
   Total BrdU-positive cells 555 
   Ngn2-positive/BrdU-positive 21% 
   Total Ngn2-positive cells 288 
   BrdU-positive/Ngn2-positive 42% 
Ngn2 and Ki67  
   Total Ki67-positive cells 1623 
   Ngn2-positive/Ki67-positive 28% 
      Ngn2-positive/Ki67+++ 7% 
      Ngn2-positive/Ki67++ 21% 
      Ngn2-positive/Ki67+ 32% 
   Total Ngn2-positive cells 575 
   Ki67-positive/Ngn2-positive 78% 
Ngn2 and BrdU  
   Total BrdU-positive cells 555 
   Ngn2-positive/BrdU-positive 21% 
   Total Ngn2-positive cells 288 
   BrdU-positive/Ngn2-positive 42% 

Sections collected from eight E13 or E14 embryos were examined for Ngn2 and Ki67 colocalization using a confocal microscope (40× objective), and sections from five embryos were similarly examined for Ngn2 and BrdU colocalization. Results were for assessment of cell cycle phases, Ki67 immunoreactivity was graded as presented in Fig. 6F. Ngn2 immunoreactivity was not graded [taking all of the +++ to +(Fig. 6E,G,I) as 'positive']here.

Close Modal

or Create an Account

Close Modal
Close Modal